ArticlePharmacological reports : PR2025
Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study.
Article in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association of germlineFrontiers in pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the proven benefit of adding palbociclib to endocrine therapy (ET) as demonstrated in pivotal clinical trials (e.g., PALOMA-2 and PALOMA-3), many patients with hormone receptor-positive (HR+) and human epidermal growth factor-2-negative (HER2−) metastatic breast cancer (MBC) still experience early disease progression. This study aimed to identify predictive biomarkers for long-term response and evaluate the impact of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) gene polymorphisms in MBC patients who had progressed on prior ET.
methodsThis prospective cohort study included 95 adult MBC patients treated with palbociclib. Demographic, laboratory, and therapeutic variables were analyzed. A genotyping assay was done using real-time polymerase chain reaction (RT-PCR).
resultsLow Ki-67 expression (< 20%) and moderate-to-severe (grade 3/4) neutropenia were associated with longer progression-free survival (PFS) (p = 0.00 and p = 0.01, respectively). Regarding adverse effects, patients carrying the minor-T-allele (CT/TT) had a lower incidence of neutropenia compared to those with the CC genotype (33.3% vs. 66.7%, p = 0.03). Patients with a baseline absolute neutrophil count (ANC) < 3.6 × 10³/mm³ had higher rates of grade 3/4 neutropenia and dose interruptions/reductions (p = 0.00). In univariate logistic regression analysis, homozygous carriers of the ABCB1 CC genotype had a higher risk of grade 3/4 neutropenia (Odds ratio (OR) = 0.333, 95% confidence interval (CI) [0.121–0.920]; p = 0.03).
conclusionKi-67 expression and grade 3/4 neutropenia were associated with PFS in MBC, suggesting their potential relevance to clinical outcomes. Additionally, pharmacogenetic polymorphisms may help explain interindividual variations in treatment safety.
Indexed as
Identifiers
41003985What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.